BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
AZN upcoming catalysts
AstraZeneca: 15 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (8 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 59 readout(s) and 18 FDA event(s). Subscribe to AZN (.ics).
Drugs: Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Pemetrexed, AZD6234, Bevacizumab, Lenvatinib, AZD0780, Osimertinib, AZD9550, AZD0901, Gemcitabine, Pembrolizumab, Paclitaxel, Benralizumab, Anifrolumab, Oleclumab, Tezepelumab, Savolitinib, Irinotecan, Capivasertib, Volrustomig, Rilvegostomig, AZD0754, AZD2287, Baxdrostat/dapagliflozin, Monalizumab, Dato-DXd, Trastuzumab deruxtecan, AZD4144, Leucovorin, Fulvestrant, Dapagliflozin, ICS-LABA, Rosuvastatin, Domvanalimab, Olaparib, Etoposide
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P1/P2 | AstraZeneca AZN | NCT06267729 Study of AZD0754 in Participants With Metastatic Prostate Cancer | Metastatic Prostate Cancer | recruiting | 60 |
| 2026-11-30 est. | P2 | AstraZeneca AZN | NCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 114 |
| 2026-12-10 est. | P2 | AstraZeneca AZN | NCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Ki | Chronic Kidney Disease and Hypertension | active not recruiting | 222 |
| 2026-12-23 est. | P3 | AstraZeneca AZN | NCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizum | Asthma | active not recruiting | 94 |
| 2026-12-31 est. | P3 | AstraZeneca AZN | NCT05303532 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab | Cancer | enrolling by invitation | 214 |
| 2027-01-04 est. | P3 | AstraZeneca AZN | NCT07000136 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Heterozygous Familial Hypercholesterolaemia | active not recruiting | 473 |
| 2027-01-06 est. | P3 | AstraZeneca AZN | NCT05925803 Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | Systemic Sclerosis; Scleroderma | active not recruiting | 314 |
| 2027-01-08 est. | P3 | AstraZeneca AZN | NCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III | Non-Small Cell Lung Cancer | active not recruiting | 1051 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Cardiovascular Disease | active not recruiting | 3103 |
| 2027-01-13 est. | P3 | AstraZeneca AZN | NCT06706817 A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 181 |
| 2027-01-18 est. | P2 | AstraZeneca AZN | NCT05374603 Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Lung Cancer | active not recruiting | 47 |
| 2027-01-29 est. | P1/P2 | AstraZeneca AZN | NCT06151964 A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | Overweight and Obesity | active not recruiting | 166 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
| 2027-02-11 est. | P2 | AstraZeneca AZN | NCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | Sepsis; Acute Kidney Injury | recruiting | 124 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11-05 est. | P1/P2 | AstraZeneca AZN | NCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Prostate Cancer | active not recruiting | 6 |
| 2026-11-02 | P3 | AstraZeneca AZN | NCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | active not recruiting | 339 |
| 2026-10-31 est. | P3 | AstraZeneca AZN | NCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | Breast Cancer | active not recruiting | 293 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherap | Carcinoma, Non-Small-Cell Lung | active not recruiting | 103 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10-23 est. | P2 | AstraZeneca AZN | NCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight | Obesity/Overweight | active not recruiting | 16 |
| 2026-10-01 | P1/P2 | AstraZeneca AZN | NCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) | RSV Respiratory Syncytial Virus | active not recruiting | 164 |
| 2026-09-30 est. | P3 | AstraZeneca AZN | NCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC | Hepatocellular Carcinoma | active not recruiting | 214 |
| 2026-09-26 est. | P2 | AstraZeneca AZN | NCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and | Chronic Kidney Disease With High Proteinuria | active not recruiting | 224 |
| 2026-09-21 | P3 | AstraZeneca AZN | NCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated | Eosinophilic Asthma | completed | 130 |
| 2026-09-03 | P2 | AstraZeneca AZN | NCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Par | Dyslipidaemia | completed | 76 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08-14 | P2 | AstraZeneca AZN | NCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18. | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 33 |
| 2026-08-10 | P2 | AstraZeneca AZN | NCT06681324 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy | Crohn's Disease | active not recruiting | 24 |
| 2026-08-10 | P3 | AstraZeneca AZN | NCT05267613 Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | Erosive Esophagitis | completed | 53 |
| 2026-08-10 | P3 | AstraZeneca AZN | NCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Non-Small Cell Lung Cancer | active not recruiting | 791 |
| 2026-07-27 est. | P3 | AstraZeneca AZN | NCT04884360 D9319C00001- 1L OC Mono Global RCT | Ovarian Cancer | active not recruiting | 366 |
| 2026-07-14 | P3 | AstraZeneca AZN | NCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | active not recruiting | 368 |
| 2026-07-10 | P3 | AstraZeneca AZN | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tu | Non-small Cell Lung Cancer | active not recruiting | 25 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-07-06 | P3 | AstraZeneca AZN | NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treat | Carcinoma; Non-Small-Cell Lung | active not recruiting | 341 |
| 2026-06-30 | P2 | AstraZeneca AZN | NCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular | Hepatocellular Carcinoma (HCC) | active not recruiting | 58 |
| 2026-06-30 est. | P2 | AstraZeneca AZN | NCT05825365 Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study | Neurofibromatosis Type 1; Plexiform Neurofibromas; Post-operative | withdrawn | |
| 2026-06-26 | P3 | AstraZeneca AZN | NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Receiv | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 1371 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
| 2026-05-26 | P2 | AstraZeneca AZN | NCT06851858 Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor A | Endocrinology; Diabetes, Type II; Obesity | completed | 69 |
| 2026-05-15 | P3 | AstraZeneca AZN | NCT03847428 Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment | Hepatocellular Carcinoma | completed | 908 |
| 2026-05-13 | P3 | AstraZeneca AZN | NCT06465485 STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma | Severe Eosinophilic Asthma | completed | 504 |
| 2026-05-13 | P3 | AstraZeneca AZN | NCT06194825 EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Card | Transthyretin Amyloid Cardiomyopathy | active not recruiting | 64 |
| 2026-05-11 | P2 | AstraZeneca AZN | NCT06862791 A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone | Obesity or Overweight | completed | 377 |
| 2026-05-04 | P2 | AstraZeneca AZN | NCT06606847 A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung | Non-Small Cell Lung Cancer | active not recruiting | 30 |
| 2026-04-30 | P2 | AstraZeneca AZN | NCT06450197 Phase IIa Study Evaluating AZD7798 in Crohn's Disease | Moderate to Severe Crohn's Disease | active not recruiting | 120 |
| 2026-04-21 | P2 | AstraZeneca AZN | NCT06897748 A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary | Chronic Obstructive Pulmonary Disease (COPD) | completed | 98 |
| 2026-04-17 | P3 | AstraZeneca AZN | NCT06502366 A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA | Asthma | completed | 424 |
| 2026-03-30 | P3 | AstraZeneca AZN | NCT05883644 Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | Advanced Hepatocellular Carcinoma | active not recruiting | 111 |
| 2026-03-16 est. | P3 | AstraZeneca AZN | NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | Triple Negative Breast Neoplasms | active not recruiting | 923 |
| 2026-03-06 | P3 | AstraZeneca AZN | NCT06040086 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1454 |
| 2026-03-04 est. | P3 | AstraZeneca AZN | NCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | Prostate Cancer | active not recruiting | 1035 |
| 2026-03-02 | P3 | AstraZeneca AZN | NCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer In | Muscle Invasive Bladder Cancer | active not recruiting | 712 |
| 2026-02-26 | P3 | AstraZeneca AZN | NCT05742802 Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1713 |
| 2026-02-23 | P3 | AstraZeneca AZN | NCT05301842 Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | Hepatocellular Carcinoma | active not recruiting | 760 |
| 2026-02-10 | P2 | AstraZeneca AZN | NCT06299826 A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure | Chronic Heart Failure | completed | 375 |
| 2026-02-04 | P2 | AstraZeneca AZN | NCT06529419 A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations | Asthma | completed | 537 |
| 2026-01-28 | P1/P2 | AstraZeneca AZN | NCT07128615 A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) | Influenza A | active not recruiting | 405 |
| 2026-01-22 | P3 | AstraZeneca AZN | NCT06067828 A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI | Chronic Obstructive Pulmonary Disease | completed | 171 |
| 2026-01-19 | P3 | AstraZeneca AZN | NCT05166889 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1132 |
| 2026-01-19 | P3 | AstraZeneca AZN | NCT05158387 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1172 |
| 2026-01-12 | P2 | AstraZeneca AZN | NCT05925530 Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resect | Non-small Cell Lung Cancer | active not recruiting | 142 |
| 2026-01-07 | P2 | AstraZeneca AZN | NCT05251259 Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma | Asthma | completed | 670 |
| 2025-12-31 | P3 | AstraZeneca AZN | NCT05043090 Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC | Papillary Renal Cell Carcinoma | active not recruiting | 148 |
| 2025-12-19 est. | P1/P2 | AstraZeneca AZN | NCT07060365 A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent | Advanced/Recurrent Ovarian Cancer | withdrawn | |
| 2025-12-19 | P2 | AstraZeneca AZN | NCT06579105 Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. | Diabetes Mellitus, Type 2 | completed | 406 |
| 2025-12-03 | P2 | AstraZeneca AZN | NCT06595238 A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity or Overweight | completed | 262 |
| 2025-11-24 | P3 | AstraZeneca AZN | NCT06344104 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants Wi | Uncontrolled Hypertension; Resistant Hypertension | completed | 326 |
| 2025-11-24 | P3 | AstraZeneca AZN | NCT05110261 Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China | Lower Respiratory Tract Infection | completed | 800 |
| 2025-11-21 | P2 | AstraZeneca AZN | NCT06579092 Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity | Obesity or Overweight | completed | 310 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.